Loading stock data…
CNTA
$39.57+0.15 (+0.38%)
Market ClosedLast close May 1
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Centessa Pharmaceuticals plc in the Healthcare sector is trading at $39.57. The stock is currently near its 52-week high of $40.26, remaining 57.3% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why CNTA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$39.57
Potential Upside
5%
Whystock Fair Value$41.55
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$44.57+12.6%
Range$38.00 – $62.00
Fundamentals
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.73%
Volume
Today's trading volume
866,209
Recent News
Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals
Backed by one-year EPS and revenue growth estimates of 21.72% and 16.23%, respectively, Eli Lilly and Company (NYSE:LLY) ranks among the best growth stocks to buy and hold in 2026. As of April 23, 2026, a majority of analysts covering the stock have a Buy rating on it; that is, 77% of all covering analysts, […]
Is This $6.3 Billion Deal a Game Changer for Eli Lilly?
It's acquiring an asset with a very promising lead drug candidate.
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Best Buy, Bilibili, Constellation Brands, CoreWeave, Nike, Starbucks, T-Mobile, and More
Pre-Market Stock Futures: Futures are trading lower this morning after negotiations with Iran failed over the weekend, and President Trump indicated the U.S. will block the Strait of Hormuz. This comes as we get set to start the first-quarter earnings season this week, as the major money-center banks and brokerage firms begin to report results ... Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Best Buy, Bilibili, Constellation Brands, CoreWeave, Nike, Starbucks, T-Mobile, and M
Looks Like M&A Week in 3 Different Sectors
Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry.
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.